{"id":752902,"date":"2023-05-01T07:35:40","date_gmt":"2023-05-01T11:35:40","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program\/"},"modified":"2023-05-01T07:35:40","modified_gmt":"2023-05-01T11:35:40","slug":"tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program\/","title":{"rendered":"TFF Pharmaceuticals Receives Additional Funding from Leidos to Advance Next-Generation Personalized Protective Biosystems under the DARPA PPB Program"},"content":{"rendered":"
\n

FORT WORTH, Texas, May 01, 2023 (GLOBE NEWSWIRE) — TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (\u201cthe Company\u201d), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that Leidos, a leading Fortune 500 information technology, engineering and science solutions and services leader, has awarded the Company additional funding under the DARPA Personalized Protective Biosystems (PPB) program to develop next-generation countermeasures for\u00a0military and healthcare personnel.<\/p>\n

The PPB research program, managed by the\u00a0Defense Advanced Research Projects Agency\u00a0(DARPA), is developing an integrated system that simultaneously reduces protective equipment needs while increasing protection for the individual against existing and future chemical and biological (CB) threats. This will be achieved through lightweight materials that protect the military or healthcare personnel from exposure to CB threats, while simultaneously providing a second layer of protection, at the tissue barrier, with bio-molecular, commensal organisms, or other technologies that protect the skin, eyes, and airway from CB threats. Successful PPB technologies could change how the military and public health communities perform in unpredictable threat environments.<\/p>\n

In April 2021, the Company entered into a 60-month, three-phase subcontract with Leidos to utilize its Thin Film Freezing platform to formulate a series of countermeasures designed to neutralize chemical and biological agents at the site of vulnerable tissue barriers, including the skin, the eyes and the respiratory system.\u00a0<\/p>\n

\u201cWe are pleased with the continued advancement of this program and our relationship with Leidos,\u201d said Harlan Weisman, M.D., Chief Executive Officer of\u00a0TFF Pharmaceuticals. \u201cThere is an unmet need to develop next-generation countermeasures to adequately protect our military and civilian populations. Our technology not only allows for delivery of various countermeasures to neutralize biochemical threats directly at the site of entry, but is also needle-free and temperature independent, making these countermeasures easily deployed and administered with ease for future biochemical threat preparedness and biodefense. We believe our Thin Film Freezing platform has extraordinary potential to improve upon numerous applications, including the development of the next generation of chemical and biological protective technologies that can significantly improve the level of protection for our military and front-line personnel.\u201d<\/p>\n

\n ABOUT LEIDOS<\/strong>\n <\/p>\n

Leidos is a Fortune 500\u00ae\u00a0information technology, engineering, and science solutions and services leader working to solve the world\u2019s toughest challenges in the defense, intelligence, homeland security, civil, and health markets. The company\u2019s 37,000 employees support vital missions for government and commercial customers. Headquartered in\u00a0Reston, Va., Leidos reported annual revenues of approximately\u00a0$11.09 billion\u00a0for the fiscal year ended\u00a0January 3, 2020. For more information, visit\u00a0www.leidos.com<\/a>.<\/p>\n

\n ABOUT TFF PHARMACEUTICALS\u2019 THIN FILM FREEZING (TFF) TECHNOLOGY<\/strong>
\n
TFF Pharmaceuticals\u2019 proprietary Thin Film Freezing (TFF) technology allows for the transformation of both existing compounds and new chemical entities into dry powder formulations exhibiting unique characteristics and benefits. The Thin Film Freezing process is a particle engineering process designed to generate dry powder particles with advantageous properties for inhalation, as well as parenteral, nasal, oral, topical and ocular routes of administration. The process can be used to engineer powders for direct delivery to the site of need, circumventing challenges of systemic administration and leading to improved bioavailability, faster onset of action, and improved safety and efficacy. The ability to deliver therapies directly to the target organ, such as the lung, allows TFF powders to be administered at lower doses compared to oral drugs, reducing unwanted toxicities and side effects. Laboratory data suggests the aerodynamic properties of the powders created by Thin Film Freezing can deliver as much as 75% of the dose to the deep lung. Thin Film Freezing does not introduce heat, shear stress, or other forces that can damage more complex therapeutic components, such as fragile biologics, and instead enables the reformulation of these materials into easily stored and temperature-stable dry powders, making therapeutics and vaccines more accessible for distribution worldwide. The advantages of Thin Film Freezing can be used to enhance traditional delivery or combined to enable next-generation pharmaceutical products.<\/p>\n

\n ABOUT<\/strong>\u00a0TFF\u00a0PHARMACEUTICALS<\/strong>
TFF Pharmaceuticals, Inc.\u00a0is a clinical-stage biopharmaceutical company engaging patented rapid freezing technology to develop and transform medicines into potent dry powder formulations for better efficacy, safety, and stability. The company\u2019s versatile Thin Film Freezing (TFF) technology platform has broad applicability to convert most any drug, including vaccines, small and large molecules, and biologics, into an elegant dry powder highly advantageous for inhalation, with improved absorption so drugs can also be delivered to the eyes, nose and topically to the skin. TFF has two lead drug candidates in the clinic: TFF VORI (Voriconazole Inhalation Powder) and TFF TAC (Tacrolimus Inhalation Powder). The Company continues collaborations with a broad array of pharmaceutical companies, academic institutions, and government partners to revolutionize healthcare around the globe. The TFF Platform is protected by 120+ patents issued or pending in the\u00a0U.S.\u00a0and internationally. To learn more about\u00a0TFF Pharmaceuticals\u00a0and its product candidates, visit the Company\u2019s website at\u00a0https:\/\/tffpharma.com<\/a>.<\/p>\n

\n SAFE<\/strong>\u00a0HARBOR<\/strong>
This press release contains forward-looking statements regarding\u00a0TFF Pharmaceuticals, Inc., including, the benefits of the Company\u2019s TFF platform and the Company\u2019s plans to add to its existing pipeline of product candidates. Those forward-looking statements involve known and unknown risks, uncertainties and other factors that could cause actual results to differ materially. Among those factors are: (i) the risk that the Company may not be able to successfully conclude clinical testing or obtain pre-market approval of any of its dry powder product candidates, (ii) success in early phases of pre-clinical and clinical trials does not ensure that later clinical trials will be successful, and interim results of a clinical trial do not necessarily predict final results, (iii) no drug product incorporating the TFF platform has received FDA pre-market approval or otherwise been incorporated into a commercial drug product, (iv) the Company has no current agreements or understandings with any large pharmaceutical companies for the development of a drug product incorporating the TFF Platform, (v) the risk that the Company will not be able to conclude a long-term commercial agreement with any third-party, and (vi) those other risks disclosed in the section \u201cRisk Factors\u201d included in the Company\u2019s Prospectus Supplement filed with the\u00a0SEC\u00a0on\u00a0November 18, 2022.\u00a0TFF Pharmaceuticals cautions readers not to place undue reliance on any forward-looking statements.\u00a0TFF Pharmaceuticals\u00a0does not undertake, and specifically disclaims, any obligation to update or revise such statements to reflect new circumstances or unanticipated events as they occur, except as required by law.<\/p>\n

\u201cThis Press Release was cleared by DARPA under Distribution Statement \u201cA\u201d (Approved for Public Release, Distribution Statement).\u201d<\/p>\n

\n Company Contact:<\/strong>
\n
Bill Begien
TFF Pharmaceuticals, Inc.
bbegien@tffpharma.com<\/a><\/p>\n

\n Investor<\/strong>
\n Relations<\/strong>
\n Contact:<\/strong>
\n
Corey Davis, Ph.D.
LifeSci Advisors
(212) 915-2577
cdavis@lifesciadvisors.com<\/u><\/a><\/p>\n

\n Media Contact: <\/strong>
\n
Raena Mina
LifeSci Communications
rmina@lifescicomms.com<\/a><\/p>\n

\n
\n
\n \n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

FORT WORTH, Texas, May 01, 2023 (GLOBE NEWSWIRE) — TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (\u201cthe Company\u201d), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that Leidos, a leading Fortune 500 information technology, engineering and science solutions and services leader, has awarded the Company additional funding under the DARPA Personalized Protective Biosystems (PPB) program to develop next-generation countermeasures for\u00a0military and healthcare personnel. The PPB research program, managed by the\u00a0Defense Advanced Research Projects Agency\u00a0(DARPA), is developing an integrated system that simultaneously reduces protective equipment needs while increasing protection for the individual against existing and future chemical and biological (CB) threats. This will be achieved through lightweight … <\/p>\n

Continue reading “TFF Pharmaceuticals Receives Additional Funding from Leidos to Advance Next-Generation Personalized Protective Biosystems under the DARPA PPB Program”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-752902","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nTFF Pharmaceuticals Receives Additional Funding from Leidos to Advance Next-Generation Personalized Protective Biosystems under the DARPA PPB Program - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"TFF Pharmaceuticals Receives Additional Funding from Leidos to Advance Next-Generation Personalized Protective Biosystems under the DARPA PPB Program - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"FORT WORTH, Texas, May 01, 2023 (GLOBE NEWSWIRE) — TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (\u201cthe Company\u201d), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that Leidos, a leading Fortune 500 information technology, engineering and science solutions and services leader, has awarded the Company additional funding under the DARPA Personalized Protective Biosystems (PPB) program to develop next-generation countermeasures for\u00a0military and healthcare personnel. The PPB research program, managed by the\u00a0Defense Advanced Research Projects Agency\u00a0(DARPA), is developing an integrated system that simultaneously reduces protective equipment needs while increasing protection for the individual against existing and future chemical and biological (CB) threats. This will be achieved through lightweight … Continue reading "TFF Pharmaceuticals Receives Additional Funding from Leidos to Advance Next-Generation Personalized Protective Biosystems under the DARPA PPB Program"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-05-01T11:35:40+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyODE5MiM1NTY0NTY4IzUwMDA4MDQ2Mg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"6 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"TFF Pharmaceuticals Receives Additional Funding from Leidos to Advance Next-Generation Personalized Protective Biosystems under the DARPA PPB Program\",\"datePublished\":\"2023-05-01T11:35:40+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program\\\/\"},\"wordCount\":1135,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyODE5MiM1NTY0NTY4IzUwMDA4MDQ2Mg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program\\\/\",\"name\":\"TFF Pharmaceuticals Receives Additional Funding from Leidos to Advance Next-Generation Personalized Protective Biosystems under the DARPA PPB Program - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyODE5MiM1NTY0NTY4IzUwMDA4MDQ2Mg==\",\"datePublished\":\"2023-05-01T11:35:40+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyODE5MiM1NTY0NTY4IzUwMDA4MDQ2Mg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODgyODE5MiM1NTY0NTY4IzUwMDA4MDQ2Mg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"TFF Pharmaceuticals Receives Additional Funding from Leidos to Advance Next-Generation Personalized Protective Biosystems under the DARPA PPB Program\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"TFF Pharmaceuticals Receives Additional Funding from Leidos to Advance Next-Generation Personalized Protective Biosystems under the DARPA PPB Program - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program\/","og_locale":"en_US","og_type":"article","og_title":"TFF Pharmaceuticals Receives Additional Funding from Leidos to Advance Next-Generation Personalized Protective Biosystems under the DARPA PPB Program - Market Newsdesk","og_description":"FORT WORTH, Texas, May 01, 2023 (GLOBE NEWSWIRE) — TFF Pharmaceuticals, Inc. (NASDAQ: TFFP) (\u201cthe Company\u201d), a clinical-stage biopharmaceutical company focused on developing and commercializing innovative drug products based on its patented Thin Film Freezing (TFF) technology platform, today announced that Leidos, a leading Fortune 500 information technology, engineering and science solutions and services leader, has awarded the Company additional funding under the DARPA Personalized Protective Biosystems (PPB) program to develop next-generation countermeasures for\u00a0military and healthcare personnel. The PPB research program, managed by the\u00a0Defense Advanced Research Projects Agency\u00a0(DARPA), is developing an integrated system that simultaneously reduces protective equipment needs while increasing protection for the individual against existing and future chemical and biological (CB) threats. This will be achieved through lightweight … Continue reading \"TFF Pharmaceuticals Receives Additional Funding from Leidos to Advance Next-Generation Personalized Protective Biosystems under the DARPA PPB Program\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program\/","og_site_name":"Market Newsdesk","article_published_time":"2023-05-01T11:35:40+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyODE5MiM1NTY0NTY4IzUwMDA4MDQ2Mg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"6 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"TFF Pharmaceuticals Receives Additional Funding from Leidos to Advance Next-Generation Personalized Protective Biosystems under the DARPA PPB Program","datePublished":"2023-05-01T11:35:40+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program\/"},"wordCount":1135,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyODE5MiM1NTY0NTY4IzUwMDA4MDQ2Mg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program\/","name":"TFF Pharmaceuticals Receives Additional Funding from Leidos to Advance Next-Generation Personalized Protective Biosystems under the DARPA PPB Program - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyODE5MiM1NTY0NTY4IzUwMDA4MDQ2Mg==","datePublished":"2023-05-01T11:35:40+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyODE5MiM1NTY0NTY4IzUwMDA4MDQ2Mg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODgyODE5MiM1NTY0NTY4IzUwMDA4MDQ2Mg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/tff-pharmaceuticals-receives-additional-funding-from-leidos-to-advance-next-generation-personalized-protective-biosystems-under-the-darpa-ppb-program\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"TFF Pharmaceuticals Receives Additional Funding from Leidos to Advance Next-Generation Personalized Protective Biosystems under the DARPA PPB Program"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/752902","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=752902"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/752902\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=752902"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=752902"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=752902"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}